Biotech’s Comeback Gains Traction As Fundamentals And Valuations Align Again

After languishing in a multi-year drought, biotech stocks are suddenly the sector everyone wants at their portfolio party. The SPDR S&P Biotech ETF climbed 18% year-to-date through Oct. 31, crushing the S&P 500’s performance. Positive catalysts like falling interest rates are cutting funding costs while boosting valuations for long-horizon firms, suggesting this turnaround has real staying power.

• UniQureQURE
  and Praxis Precision MedicinesPRAX
  are up 483% and 145% this past year, thanks to strong clinical trial results.
• Biotech Mergers and acquisitions are surging with Regulus Therapeutics, Chimerix, and Intra-Cellular Therapies all rising amid buyout speculation.

The prescription for success: Tariff worries are easing as 17 major biopharma companies expand US manufacturing, drug pricing pressure has softened, and FDA timelines have steadied. The post-COVID shakeout also cleared out weaker players, leaving a stronger field. William Blair’s biotech analyst Myles Minter favors Ascendis PharmaASND

, AlkermesALKS

, and BridgeBio PharmaBBIO

for their strong pipelines and launches. As Stifel’s Paul Matteis puts it, “The sector’s run has been driven by a number of credible fundamental factors that seem mostly sustainable.”